

1 **Title: Association between obesity and hospitalization in mild COVID-19 young adult**  
2 **outpatients in Brazil: a prospective cohort study**

3

4 Ivaine Tais Sauthier Sartor<sup>1\*</sup>, Caroline Nespolo de David<sup>1\*</sup>, Gabriela Heiden Telo<sup>2</sup>, Gabriela  
5 Oliveira Zavaglia<sup>1</sup>, Ingrid Rodrigues Fernandes<sup>1</sup>, Luciane Beatriz Kern<sup>1</sup>, Márcia Polese-  
6 Bonatto<sup>1</sup>, Thaís Raupp Azevedo<sup>1</sup>, Amanda Paz Santos<sup>1</sup>, Walquiria Aparecida Ferreira de  
7 Almeida<sup>3</sup>, Victor Bertollo Gomes Porto<sup>3</sup>, Fernanda Hammes Varela<sup>1,2</sup>, Marcelo Comerlato  
8 Scotta<sup>1,2</sup>, Regis Goulart Rosa<sup>1</sup>, Renato T. Stein<sup>1,2</sup>.

9

10 \*These authors contributed equally to this manuscript.

11 1. Social Responsibility – PROADI-SUS, Hospital Moinhos de Vento, Porto Alegre, Brazil

12 2. School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre,

13 Brazil

14 3. General Coordination, Programa Nacional de Imunização, Brazilian Ministry of Health

15

16 Corresponding author: Ivaine Tais Sauthier Sartor, [ivaine.sartor@hmv.org.br](mailto:ivaine.sartor@hmv.org.br), phone: 55-51-

17 983016858, address: Ramiro Barcelos street, 630/1002, ZIP-Code: 90035-001, Porto

18 Alegre, Brazil

19

20 **Abstract**

21 **Background/Objectives**

22 The aim of this study was to evaluate the association between obesity and hospitalization in  
23 mild COVID-19 adult outpatients in Brazil.

24 **Subjects/Methods**

25 Adults with signs and symptoms suggestive of acute SARS-CoV-2 infection who sought two  
26 hospitals (one public and one private) emergency department were prospectively enrolled.  
27 Patients with confirmed COVID-19 at inclusion were followed by phone calls at day (D) D7,  
28 D14 and D28. Multivariable logistic regression models were employed to explore the  
29 association between obesity and other potential predictors for hospitalization.

30 **Results**

31 A total of 1,050 participants were screened, 310 were diagnosed with COVID-19 by RT-  
32 PCR. Median age was 37.4 (IQR 29.8-45.0) years, and 186 (60.0%) were female. Duration  
33 of symptoms was 3.0 (IQR 2.0-5.0) days, and 10.0 (IQR 8.0-12.0) was the median number  
34 of symptoms at inclusion. A total of 98 (31.6%) were obese, and 243 (78.4%) had no  
35 previous medical conditions. Twenty three participants (23/310, 7.4%) required  
36 hospitalization during the period. After adjusting, obesity ( $BMI \geq 30.0 \text{ kg/m}^2$ ) ( $OR=2.69$ , 95%CI  
37 1.63-4.83,  $P<0.001$ ) and older age ( $OR=1.05$ , 95%CI 1.01-1.09,  $P<0.001$ ), were significantly  
38 associated with higher risks of hospitalization.

39 **Conclusions**

40 Obesity, followed by aging, was the main factor associated with hospital admission for  
41 COVID-19 in a young population in a low-middle income country. Our findings highlighted  
42 the need for actions to promote additional protection for obese population, such as  
43 vaccination, and to encourage lifestyle changes.

44

45 **Keywords:** mild COVID-19, noncritical COVID-19, young adults, follow-up, outpatients,  
46 hospitalization

47

## 48 **Introduction**

49 Coronavirus disease 2019 (COVID-19) has brought large numbers of patients to medical  
50 attention within a short time span for care of a previously undescribed illness, challenging  
51 health services and providers to deliver time-sensitive interventions under difficult  
52 circumstances. Since the first cases of COVID-19 were documented in China in late  
53 December 2019, the epidemiologic focus has largely been on establishing the severity of  
54 disease and outcomes among severe patients<sup>1,2</sup>. Older age and some metabolic disorders  
55 such as diabetes were early found to be predictors of hospital admission and mortality in  
56 patients with COVID-19<sup>3</sup>.

57 The COVID-19 pandemic has occurred at a time when the prevalence of obesity is  
58 increasing all around the world. Obesity is a well-established risk factor for metabolic non-  
59 communicable diseases such as type 2 diabetes and hypertension, highly influencing most  
60 major cardiovascular diseases. With the worldwide spread of acute respiratory syndrome  
61 coronavirus 2 (SARS-CoV-2), obesity has also emerged as an independent risk factor for  
62 severe COVID-19, likely related to the adipose tissue inflammation's effects on the immune  
63 system, besides all the metabolic dysfunction associated<sup>4</sup>. In a recent United States  
64 Department of Health and Human Services/Centers for Disease Control and Prevention  
65 publication, overweight and obesity were both identified as risk factors for the need of  
66 mechanical ventilation related to COVID-19, while only obesity was associated with  
67 hospitalization and death in an adult cohort of inpatients<sup>5</sup>. However, as risk estimated for  
68 severe COVID-19-associated outcomes were measured mostly among adults who received  
69 care at a hospital, the current knowledge about the impact of obesity on COVID-19 hospital  
70 admission may possibly be overestimated due to a selection bias, as most studies evaluated  
71 only inpatients.

72 Few studies were developed in mild COVID-19 adult outpatients, especially in low-middle  
73 income countries (LMIC). Given the uncertainty regarding outcomes in this low-risk  
74 outpatient population, and considering the exponential rise in the prevalence of obesity and  
75 its association with severe forms of the disease, this study aimed to evaluate the association

76 between obesity and hospitalization in mild COVID-19 adult outpatients in Brazil. We also  
77 aimed to describe the clinical characteristics of COVID-19 outpatients and identify other  
78 predictors of hospitalization.

79

## 80 **Materials/Subjects and Methods**

### 81 **1. Study design and population**

82 This is a prospective cohort study with data collected in referral hospitals from Southern  
83 Brazil, one public (Hospital Restinga e Extremo Sul) and the other from the private health  
84 system (Hospital Moinhos de Vento). From 13<sup>th</sup> May to 14<sup>th</sup> September 2020 we assessed  
85 adult ( $\geq 18$  years old) outpatients who had a visit in the emergency department (ED) health  
86 system for COVID-19 symptoms. Inclusion criteria were presenting at least one sign or  
87 symptom suggestive of COVID-19 (cough, fever, or sore throat), within 14 days of onset of  
88 symptoms. We then created a cohort of those with confirmed COVID-19, defined as a  
89 positive result on real-time reverse transcriptase (RT-PCR) for SARS-CoV-2.

### 90 **2. Study procedures**

91 At baseline, clinical, demographic, comorbidities, and signs or symptoms suggestive of  
92 COVID-19 data were collected. All participants underwent bilateral nasopharyngeal and  
93 oropharyngeal swab collection for SARS-CoV-2 detection via RT-PCR assay. The samples  
94 were analyzed in the Molecular Biology Laboratory at Hospital Moinhos de Vento, as  
95 described previously<sup>6</sup>. Reported weight and height were used to calculate body mass index  
96 (BMI). Participants were followed by phone interviews at 7, 14 and 28 days after seeking  
97 care for COVID-19 symptoms (study baseline). Up to ten telephone call attempts were made  
98 during a period of three days from the D7, D14 or D28. When necessary, text messages  
99 were sent in order to notify that the researchers were trying to contact them. If there was no  
100 success in contacting one of the time points, the questions were asked retroactively on the  
101 next call. The questions were asked directly to the participant or, in his absence or  
102 incapacity, for a person authorized by him at baseline. The participant was considered lost

103 when it was not possible to make any contact in different day periods (including failure in 10  
104 call attempts or time exceeded considering 3-day window) within the 28-day follow-up.

105 During the follow up interviews, participants were asked about the need of hospital  
106 admission, use of supplemental oxygen, admission at intensive care units (ICU), and use of  
107 invasive mechanical ventilation. All data were collected by trained researchers and using  
108 standardized questionnaires developed for the study in the Research Electronic Data  
109 Capture software (REDCap)<sup>7,8</sup>.

110 The outcome of interest was unplanned hospital admission in the period of 28 days. In order  
111 to predict the outcome, demographic and clinical characteristics as age at time of enrollment  
112 (years), sex, days of onset of symptoms, racial or ethnic group, active or second hand  
113 smoke at home, hospital at inclusion, number of symptoms and number of medical  
114 conditions were considered. In order to evaluate obesity as a predictor for the outcome of  
115 interest, we used BMI and participants were classified as non-obese (<30.0 kg/m<sup>2</sup>), and  
116 obesity (≥30.0 kg/m<sup>2</sup>).

### 117 **3. Statistical analyses**

118 Data normality assumptions were verified using the Shapiro-Wilk test for continuous  
119 variables, median values and interquartile ranges (IQR) were calculated, and two-tailed  
120 Mann-Whitney-Wilcoxon test was used. Pearson's Chi-square or Fisher's exact tests were  
121 used to evaluate proportions. Uni and multivariable logistic regression analyses were  
122 performed to assess the predictors of hospitalization considering the follow up period of 28  
123 days after having a COVID-19 health care visit (study baseline). The association between  
124 obesity and hospitalization was assessed using multiple logistic regression models with  
125 adjustment for relevant covariates (hospital at inclusion; years of education; number of  
126 medical conditions (none, one, two or more); days of onset of symptoms to inclusion;  
127 number of symptoms (≤8, 9-10, 11-12, ≥13); and cardiovascular diseases, which includes:  
128 ischemic heart disease, heart failure and hypertension). We performed additional models  
129 including covariates considered risk factors to hospitalization in order to assess consistency

130 and risk of bias. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. All  
131 data preprocessing and analyses were performed in R 3.5.0 statistical software<sup>9</sup>.

#### 132 **4. Ethics**

133 The study was performed in accordance with the Decree 466/12<sup>10</sup> of the National Health  
134 Council and Good Clinical Practice Guidelines, after approval by the Institutional Review  
135 Board (IRB n° 4.637.933). All participants included in this study provided written informed  
136 consent.

137

#### 138 **Results**

139 In this study 1,050 subjects were screened and 13 were excluded (9 for not meeting  
140 inclusion criteria, 2 for not consenting, and 1 withdrew consent, and 1 without SARS-CoV-2  
141 RT-PCR result), and 727 participants with negative RT-PCR results. A total of 310 adults  
142 with confirmed SARS-CoV-2 were included. The success in the 28-days follow-up was  
143 obtained for 297 (95.8%) participants, as shown in Figure 1.

144 At baseline, the median participants' age was 37.4 years (IQR, 29.8-45.0). Out of 310  
145 participants, 186 (60.0%) were female, 222 (71.6%) declared themselves caucasian, and  
146 173 (55.8%) were from the public hospital. The median days of symptoms was 3.0 (IQR, 2.0-  
147 5.0), and 10.0 (IQR 8.0-12.0) was the median number of symptoms at inclusion. The most  
148 commonly reported symptoms were headache (90.6%), cough (87.4%), malaise (77.1%),  
149 and myalgia (76.5%). Few participants were active or second hand smoker at home (17.7%),  
150 and more than half was overweight (112, 36.1%) or obese (98, 31.6%). Most participants  
151 (78.4%) had no previous medical conditions. Hypertension (12.6%), asthma (6.1%) and type  
152 1 or type 2 diabetes (3.5%) were the most frequent baseline comorbidities reported.

153 At the 28-day follow-up, 23/310 (7.4%) participants required hospitalization. The median BMI  
154 of hospitalized participants was 32.4kg/m<sup>2</sup> (IQR, 30.2-34.1), whereas for the outpatients was  
155 27.7kg/m<sup>2</sup> (IQR, 24.3-30.5) (P<0.001). The median of the duration from onset of symptoms  
156 at the hospitalizations and at enrollment was 14.0 (IQR, 8.0-17.5) and 9.5 (IQR, 6.0-13.5)  
157 days, respectively. During the hospitalization, 15/23 (65.2%) participants required only use of

158 supplemental oxygen, 6/23 (26.1%) were admitted to ICU, 2/23 (8.7%) used invasive  
159 mechanical ventilation, and one participant died (1/23, 4.3%).

160 Participants who required hospitalization were significantly older ( $P=0.005$ ) and obese  
161 ( $P<0.001$ ) compared with those who did not. No other differences were observed between  
162 groups, as shown in Table 1. In multivariable logistic regression analysis age and obesity  
163 remained as an important predictor of hospital admission in our cohort (age: OR=1.05,  
164 95%CI 1.01-1.09; obesity: OR=2.69, 95%CI 1.63-4.83). When adjusted for hospital of  
165 inclusion, years of education, number of medical conditions, cardiovascular diseases, days  
166 of onset of symptoms and number of symptoms at enrollment, age and obesity remained  
167 associated with hospitalization, as shown in Figure 2.

168 Among the 15 obese participants with COVID-19 admitted at hospital within 28 days of  
169 follow up, the median age was 42.0 years (IQR, 37.2-51.7), 9 (60.0%) were male, 8 (53.3%)  
170 were admitted at private hospitals. Four (26.6%) participants reported underlying medical  
171 conditions (hypertension, diabetes mellitus, asthma, chronic obstructive pulmonary disease  
172 or ischemic heart disease). The median days of onset of symptoms to hospitalization was  
173 8.0 (IQR, 7.0-9.0), and the median days from the ED sought to hospitalization was 5.5 (IQR,  
174 4.0-7.0). Ten (66.7%) participants required supplemental oxygen, 4 (26.7%) were admitted  
175 to ICU, one needed invasive mechanical ventilation (6.7%) and one participant died (6.7%).

176

## 177 **Discussion**

178 Obesity is a recognized risk factor associated with worse outcomes related to COVID-19;  
179 however, most of the previous studies were carried out in a population of patients already  
180 admitted to the hospital or at a high admission rate due to the disease<sup>11</sup>. In this study, we  
181 evaluated the risk of hospital admissions in LMIC, through an outpatient cohort of young  
182 patients with symptoms of COVID-19 enrolled early in the course of the disease. Our results  
183 identified, for a low-risk and young population, that obesity was the main predictor of  
184 hospitalization for COVID-19, with approximately 3-fold increase in the risk of hospital  
185 admission in comparison to non-obese patients.

186 The world is still struggling to fight the COVID-19 pandemic. According to the World Health  
187 Organization (WHO), the mortality rate from COVID-19 is 0.5-1.0%<sup>12</sup>, while the  
188 hospitalization rate for the disease is 5.0-15.0%. Based on currently available information,  
189 the Centers for Disease Control and Prevention has identified severe obesity as an  
190 important risk factor for worse prognosis and higher mortality in patients with COVID-19,  
191 while any degree of obesity has been associated with COVID-19 poor prognosis. In our  
192 study, 7.4% of our sample required hospital admission, similarly to data from literature. Most  
193 participants were overweight/obese at baseline, but only obesity predicted the main  
194 outcome. In a meta-analysis of 75 studies<sup>13</sup>, obesity had a 46.0% higher risk for being  
195 COVID-19 positive, a 113.0% higher risk of being hospitalized, and a 48.0% increased  
196 mortality. There are many mechanisms that jointly may explain this impact; although the  
197 effect of obesity on the immune system remains not completely established, it appears to  
198 have an effect independent of coexisting risk factors. Data from literature also identify a  
199 dose-response relationship between BMI and COVID-19 worse outcomes<sup>5</sup>.

200 In addition to metabolic factors that seem to impact the severity of COVID-19, advanced age  
201 has been identified as one of the major factors associated with worse outcomes in the  
202 pandemic, being one of the most important predictors of hospital admission<sup>11</sup>. In our sample,  
203 the mean age of participants was younger than most studies in the literature; however, we  
204 also identified an increased risk of hospitalization for COVID-19 with each increased year of  
205 age. Concerns brought by our data include the fact that the predictors of higher risk for  
206 COVID-19 involve populations especially in need of care by health system<sup>5</sup>. The obese and  
207 elderly individuals are possibly the ones that will be mostly compromised by the social  
208 distancing that the pandemic generates, possibly resulting in worse health habits, such as  
209 physical inactivity and unhealthy eating habits, besides increased emotional distress. This  
210 could further aggravate the risk related to COVID-19 for this population, unless  
211 governmental and health measures, such as vaccination and strategies to increase  
212 consumption of healthier foods, stimulate physical activity and promote mental health<sup>13</sup>,  
213 aimed at the health of this population, starts to be prioritized.



214 Our study has limitations. Our analysis was based on a convenience sample. Moreover, our  
215 participants represent a single geographic region of a heterogeneous country, such as  
216 Brazil. However, worldwide prevalence of obesity is a public health concern and our findings  
217 are in line with previous reports<sup>14–17</sup>. As another point to address, the two centers included in  
218 this study represent different populations, public and private, which may characterize  
219 different clusters and limit the interpretation of our results for the sample as a whole. Also,  
220 most of our data represents self-report and may be subject to bias. Despite that, we believe  
221 that our results add to the literature as they represent an outpatient prospective cohort of  
222 young individuals with low risk for complications related to COVID-19 in a LMIC, identifying  
223 important risk predictors for this population. Moreover, a similar impact of obesity was  
224 consistently found despite adjusting for several possible confounders.

225 In conclusion, our data identified that obesity, in addition to age, was the most important risk  
226 factor predicting hospital admission for COVID-19 in a young population in Southern Brazil.  
227 These results highlight the importance of health support strategies aimed at this population,  
228 in order to promote additional protection, such as vaccination, and to encourage lifestyle  
229 changes.

230

### 231 **Acknowledgments**

232 We thank the Scientific Committee of the Research Support Nucleus (NAP) of Moinhos de  
233 Vento Hospital for technical-scientific consultancy. We thank the inclusion personal,  
234 laboratory team, and site staff from Hospital Moinhos de Vento and from Hospital Restinga e  
235 Extremo Sul.

236

### 237 **Funding**

238 This work was supported by the Brazilian Ministry of Health, through the Institutional  
239 Development Program of the Brazilian National Health System (PROADI-SUS) in  
240 collaboration with Hospital Moinhos de Vento. The Ministry of Health had no role in study

241 design, sample and data collection, data analysis and interpretation, as well as in the  
242 decision to publish.

243

#### 244 **Competing Interests**

245 The authors declare no competing financial interests.

246

#### 247 **References**

248 1 Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A *et al.* Baseline  
249 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to  
250 ICUs of the Lombardy Region, Italy. *JAMA* 2020; **323**: 1574.

251 2 Altonen BL, Arreglado TM, Leroux O, Murray-Ramcharan M, Engdahl R. Characteristics,  
252 comorbidities and survival analysis of young adults hospitalized with COVID-19 in New  
253 York City. *PloS One* 2020; **15**: e0243343.

254 3 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med* 2020; **383**: 2451–  
255 2460.

256 4 Huang Y, Lu Y, Huang Y-M, Wang M, Ling W, Sui Y *et al.* Obesity in patients with COVID-  
257 19: a systematic review and meta-analysis. *Metabolism* 2020; **113**: 154378.

258 5 Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucusky MS, Lange SJ *et al.*  
259 Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit  
260 Admission, Invasive Mechanical Ventilation, and Death — United States, March–  
261 December 2020. *Morb Mortal Wkly Rep* 2021; **70**: 355–361.

262 6 Polese-Bonatto M, Sartor ITS, Varela FH, Gianinni GLT, Azevedo TR, Kern LB *et al.*  
263 Children have similar RT-PCR cycle threshold for SARS-CoV-2 in comparison with adults.  
264 *medRxiv* 2021; : 2021.04.20.21255059.

265 7 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic  
266 data capture (REDCap)--a metadata-driven methodology and workflow process for  
267 providing translational research informatics support. *J Biomed Inform* 2009; **42**: 377–381.

268 8 Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L *et al.* The REDCap

- 269 consortium: Building an international community of software platform partners. *J Biomed*  
270 *Inform* 2019; **95**: 103208.
- 271 9 R: The R Project for Statistical Computing. <https://www.r-project.org/> (accessed 24  
272 Jun2021).
- 273 10 Ministério da Saúde.  
274 [https://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466\\_12\\_12\\_2012.html](https://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466_12_12_2012.html)  
275 (accessed 13 Jul2021).
- 276 11 Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y *et al.*  
277 Factors associated with hospital admission and critical illness among 5279 people with  
278 coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 2020; **369**:  
279 m1966.
- 280 12 Estimating mortality from COVID-19: Scientific brief, 4 August 2020.  
281 [https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Sci-Brief-Mortality-](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1)  
282 2020.1 (accessed 30 Jul2021).
- 283 13 Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH *et al.* Individuals with  
284 obesity and COVID-19: A global perspective on the epidemiology and biological  
285 relationships. *Obes Rev Off J Int Assoc Study Obes* 2020; **21**: e13128.
- 286 14 Sales-Peres SH de C, de Azevedo-Silva LJ, Bonato RCS, Sales-Peres M de C, Pinto  
287 AC da S, Santiago Junior JF. Coronavirus (SARS-CoV-2) and the risk of obesity for  
288 critically illness and ICU admitted: Meta-analysis of the epidemiological evidence. *Obes*  
289 *Res Clin Pract* 2020; **14**: 389–397.
- 290 15 Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A *et al.* High  
291 Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-  
292 CoV-2) Requiring Invasive Mechanical Ventilation. *Obes Silver Spring Md* 2020; **28**:  
293 1195–1199.
- 294 16 Nakeshbandi M, Maini R, Daniel P, Rosengarten S, Parmar P, Wilson C *et al.* The  
295 impact of obesity on COVID-19 complications: a retrospective cohort study. *Int J Obes*  
296 2020; **44**: 1832–1837.

297 17 Kang Z, Luo S, Gui Y, Zhou H, Zhang Z, Tian C *et al.* Obesity is a potential risk factor  
298 contributing to clinical manifestations of COVID-19. *Int J Obes* 2020; **44**: 2479–2485.  
299

300 **Figure 1.** Study flowchart. Thirty three participants out of 297 answered the questions  
301 retroactively since there was no success in contact at that time point. Twelve responsible  
302 family members were the respondents. (RT-PCR) Reverse transcription polymerase chain  
303 reaction. (SARS-CoV-2) Severe acute respiratory syndrome coronavirus 2.

304

305 **Figure 2.** Forestplot of multivariable logistic regression models adjusting age and obesity for  
306 the covariates: hospital of inclusion (reference: private hospital at inclusion), years of  
307 education (reference: 11 years or less, which corresponds to complete high school  
308 education), number of medical conditions (reference: none), cardiovascular diseases  
309 (reference: no), days of onset of symptoms (continuous) and number of symptoms  
310 (reference:  $\leq 8$  symptoms) at enrollment. \*Number of medical conditions comprised the sum  
311 of cases of: hypertension, asthma, diabetes mellitus type 1 or 2, cancer, chronic obstructive  
312 pulmonary disease, ischemic heart disease, heart failure, human immunodeficiency virus  
313 and previous transplantation (none, one, two or more). \*\*Cardiovascular diseases comprised  
314 the presence of: ischemic heart disease, heart failure or hypertension. (yr) years.

**Table 1.** Demographic and clinical characteristics of included subjects. (IQR) interquartile range. (yr) years. (BMI) body mass index. (COPD) chronic obstructive pulmonary disease. (ED) emergency department. (ICU) intensive care unit.

| Characteristics                                  | Participants at inclusion (n = 310) | Losses (n = 13)  | Participants that needed hospitalization (n = 23) | Participants without hospitalization (n = 274) | P                 | Hospitalized obese participants (n = 15) |
|--|-------------------------------------|------------------|---|--|-------------------|--|
| Age, median (IQR)                                | 37.4 (29.8-45.0)                    | 44.2 (33.2-47.0) | 42.0 (36.5-51.7)                                  | 36.8 (29.2-44.0)                               | <b>0.005*</b>     | 42.0 (37.2-51.7)                         |
| Female sex, n (%)                                | 186 (60.0)                          | 7 (53.8)         | 12 (52.2)   | 167 (60.9)                                     | 0.55†             | 6 (40.0)                                 |
| Active or second hand smoker at home, n (%)      | 55 (17.7)                           | NI               | 4 (17.4)  | 51 (18.6)                                      | 1.00‡             | 1 (6.7)                                  |
| <b>Years of education</b>                        |                                     |                  |   |  |                   |  |
| 11 yr or less, n (%)                             | 156 (50.3)                          | NI               | 13 (56.5)   | 143 (52.2)                                     | 0.85†             | 8 (53.3)                                 |
| 12 yr or more, n (%)                             | 141 (45.5)                          | NI               | 10 (43.5)   | 131 (47.8)                                     |                   | 7 (46.7)                                 |
| <b>Nutritional status</b>                        |                                     |                  |   |  |                   |  |
| Non-obesity (BMI<30.0 kg/m <sup>2</sup> ), n (%) | 201 (64.8)                          | 10 (76.9)        | 5 (21.7)  | <b>186 (67.9)</b>                              | <b>&lt;0.001†</b> | -  |
| Obesity (BMI≥30.0 kg/m <sup>2</sup> ), n (%)     | 98 (31.6)                           | 3 (23.1)         | <b>15 (65.2)</b>                                  | 80 (29.2)                                      |                   | 15 (100.0)                               |
| <b>Hospital system at inclusion</b>              |                                     |                  |   |  |                   |  |
| Private hospital, n (%)                          | 137 (44.2)                          | 2 (15.4)         | 11 (47.8)   | 124 (45.3)                                     | 0.98†             | 8 (53.3)                                 |
| Public hospital, n (%)                           | 173 (55.8)                          | 11 (84.6)        | 12 (52.2)   | 150 (54.7)                                     |                   | 7 (46.7)                                 |
| <b>Racial or ethnic group</b>                    |                                     |                  |   |  |                   |  |

|  |               |               |               |               |       |               |
|--|---------------|---------------|---------------|---------------|-------|---------------|
| Caucasian, n (%)                         | 222 (71.6)    | NI            | 16 (69.6)     | 206 (75.2)    | 0.73† | 11 (73.3)     |
| Non-caucasian, n (%)                     | 75 (24.2)     | NI            | 7 (30.4)      | 68 (24.8)     |       | 4 (26.7)      |
| <b>Duration of symptoms at inclusion</b> |               |               |               |               |       |               |
| Days, median (IQR)                       | 3.0 (2.0-5.0) | 3.0 (2.0-5.0) | 3.0 (2.0-3.0) | 3.0 (2.0-5.0) | 0.30* | 2.0 (2.0-3.0) |
| <b>Number of symptoms</b>                |               |               |               |               |       |               |
| 2-8, n (%)                               | 95 (30.6)     | 1 (7.7)       | 8 (34.8)      | 86 (31.4)     | 0.69† | 5 (33.3)      |
| 9-10, n (%)                              | 82 (26.5)     | 3 (23.1)      | 7 (30.4)      | 72 (26.3)     |       | 5 (33.3)      |
| 11-12, n (%)                             | 74 (23.9)     | 5 (38.5)      | 3 (13.0)      | 66 (24.1)     |       | 2 (13.3)      |
| ≥13, n (%)                               | 59 (19.0)     | 4 (30.8)      | 5 (21.7)      | 50 (18.2)     |       | 3 (20.0)      |
| <b>Underlying medical conditions</b>     |               |               |               |               |       |               |
| Hypertension, n (%)                      | 39 (12.6)     | 1 (7.7)       | 5 (21.7)      | 33 (12.0)     | 0.21‡ | 3 (20.0)      |
| Asthma, n (%)                            | 19 (6.1)      | 1 (7.7)       | 1 (4.3)       | 17 (6.2)      | 1.00‡ | 1 (6.7)       |
| Diabetes mellitus type 1 or 2, n (%)     | 11 (3.5)      | 2 (15.4)      | 1 (4.3)       | 8 (2.9)       | 0.58‡ | 1 (6.7)       |
| Cancer, n (%)                            | 5 (1.6)       | 0 (0.0)       | 0 (0.0)       | 5 (1.8)       | 1.00‡ | 0 (0.0)       |
| COPD, n (%)                              | 4 (1.3)       | 0 (0.0)       | 1 (4.3)       | 3 (1.1)       | 0.31‡ | 1 (6.7)       |
| Ischemic heart disease, n (%)            | 3 (1.0)       | 0 (0.0)       | 1 (4.3)       | 2 (0.7)       | 0.24‡ | 1 (6.7)       |
| Heart failure, n (%)                     | 1 (0.3)       | 0 (0.0)       | 0 (0.0)       | 5 (1.8)       | 1.00‡ | 0 (0.0)       |

|   |               |           |               |            |       |               |
|---|---------------|-----------|---------------|------------|-------|---------------|
| HIV, n (%)  | 1 (0.3)       | 0 (0.0)   | 0 (0.0)       | 1 (0.4)    | 1.00‡ | 0 (0.0)       |
| Previous transplantation, n (%)                               | 1 (0.3)       | 0 (0.0)   | 0 (0.0)       | 1 (0.4)    | 1.00‡ | 0 (0.0)       |
| Previous chemotherapy, n (%)                                  | 0 (0.0)       | 0 (0.0)   | 0 (0.0)       | 0 (0.0)    | -     | 0 (0.0)       |
| Cardiovascular diseases**, n (%)                              | 39 (12.6)     | 1 (7.7)   | 5 (21.7)      | 33 (12.0)  | 0.21‡ | 1 (6.7)       |
| <b>Number of medical conditions</b>                           |               |           |               |            |       |               |
| None, n (%)   | 243 (78.4)    | 10 (76.9) | 17 (73.9)     | 216 (78.8) | 0.63† | 11 (73.3)     |
| One, n (%)  | 52 (16.8)     | 2 (15.4)  | 4 (17.4)      | 46 (16.8)  |       | 2 (13.3)      |
| Two or more, n (%)  | 15 (4.8)      | 1 (7.7)   | 2 (8.7)       | 12 (4.4)   |       | 2 (13.3)      |
| <b>Hospitalization</b>  |               |           |               |            |       |               |
| Yes, n (%)  | 23 (7.4)      | -         | -             | -          | -     | -             |
| Days after onset of symptoms to hospitalization, median (IQR) | 8.0 (7.0-9.5) | -         | 8.0 (7.0-9.8) | -          | -     | 8.0 (7.0-9.0) |
| Days from the ED sought to hospitalization, median (IQR)      | 5.0 (4.0-7.0) | -         | 5.0 (4.0-7.0) | -          | -     | 5.5 (4.0-7.0) |
| Use of supplemental oxygen, n (%)                             | 15 (4.8)      | -         | 15 (65.2)     | -          | -     | 10 (66.7)     |
| Admission at ICU, n (%)                                       | 6 (1.9)       | -         | 6 (26.1)      | -          | -     | 4 (26.7)      |
| Use of invasive mechanical ventilation, n (%)                 | 2 (0.6)       | -         | 2 (8.7)       | -          | -     | 1 (6.7)       |
| Deaths, n (%)   | 1 (0.3)       | -         | 1 (4.3)       | -          | -     | 1 (6.7)       |



|  |  |                   |   |  |
|--|--|-------------------|---|--|
| <b>**Cardiovascular diseases</b><br>comprised: ischemic heart disease,<br>heart failure and hypertension |  | NI = not informed | * Mann-Whitney-Wilcoxon test; † Pearson's Chi-squared test; ‡ Fisher's exact test |  |
|--|--|-------------------|---|--|



